Evidence map›Paper›PMID 31513727›Full record

ArticleBiotechnology progress2020

Process characterization strategy for a precipitation step for host cell protein reduction.

Jessica Prentice, Diemchi Vu, David Robbins, Gisela Ferreira

Abstract read
In one paragraph

Article in Biotechnology progress, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jessica PrenticeAstraZeneca, Gaithersburg, Maryland.ORCID 0000-0002-1719-103X
Diemchi VuAstraZeneca, Gaithersburg, Maryland.
David RobbinsAstraZeneca, Gaithersburg, Maryland.
Gisela FerreiraAstraZeneca, Gaithersburg, Maryland.ORCID 0000-0001-8357-3004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Process characterization using QbD approaches has rarely been described for precipitation steps used for impurity removal in biopharmaceutical processes. We propose a two-step approach for process characterization in which the first step focuses on product quality and the second focuses on process performance. This approach provides an efficient, streamlined strategy for the characterization of precipitation steps under the Quality by Design paradigm. This strategy is demonstrated by a case study for the characterization of a precipitation using sodium caprylate to reduce host cell proteins (HCP) during a monoclonal antibody purification process. Process parameters were methodically selected through a risk assessment based on prior development data and scientific knowledge described in the literature. The characterization studies used two multivariate blocks to decouple and distinguish the impact of product quality (e.g., measured HCP of the recovered product from the precipitation) and process performance (e.g., step yield). Robustness of the precipitation step was further demonstrated through linkage studies across the overall purification process. HCP levels could be robustly reduced to ≤100 ppm in the drug substance when the precipitation step operated within an operation space of ≤1% (m/v) sodium caprylate, pH 5.0-6.0, and filter flux ≤300 L/m

Indexed as

Chemical PrecipitationAnimalsCaprylatesCells, CulturedCHO CellsCricetulusHumansHydrogen-Ion ConcentrationImmunoglobulin GOxidation-ReductionCaprylatesImmunoglobulin Goctanoic acidhost cell proteinprecipitationprocess characterizationQbD

Identifiers

PMID31513727
PMCPMC7027468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.